Target intelligence / Profile preview

Ataxin 8 opposite strand long non-coding RNA (ATXN8OS)

Target
ATXN8OS
Molecular classification
Long non-coding RNA (lncRNA), Antisense RNA, Non-protein coding RNA
01

Overview

Ataxin 8 opposite strand long non-coding RNA (ATXN8OS) is an antisense transcript located on chromosome 13q21. It is classified as a long non-coding RNA (lncRNA) and does not encode a protein. ATXN8OS has pleiotropic roles in normal physiology and disease. In spinocerebellar ataxia type 8 (SCA8), expanded trinucleotide repeats in ATXN8OS are pathogenic, leading to neurodegeneration[2]. In cancer, ATXN8OS is overexpressed and acts via competing endogenous RNA (ceRNA) mechanisms, notably by sequestering microRNAs such as miR-204, which results in enhanced cell proliferation and invasion in breast cancer[1]. In gliomas, ATXN8OS suppresses temozolomide resistance by promoting ferroptosis through the ADAR/GLS2 pathway[3]. Functionally, ATXN8OS is implicated in cell cycle regulation and can serve as a prognostic biomarker in cancer. There are currently no drugs directly targeting ATXN8OS, but its molecular interactions offer promising therapeutic and diagnostic opportunities.

Other names
Putative protein ATXN8OSKLHL1ASSCA8NCRNA00003ATXN8 opposite strand (non-protein coding)Spinocerebellar ataxia 8kelch-like 1 antisensenon-protein coding RNA 3ataxin 8 opposite strand
02

Mechanism of action

Acts as a ceRNA by sequestering specific microRNAs (notably miR-204) to regulate downstream targets; Regulates chemoresistance and ferroptosis in glioma through ADAR/GLS2 pathway

03

Biological functions

Regulation of gene expression via competing endogenous RNA (ceRNA) mechanismsSequestration of microRNAs (e.g., miR-204)Modulation of cell proliferationModulation of cell invasionCell cycle regulationPromotion of ferroptosisRegulation of chemotherapy resistance (e.g., temozolomide-resistance in glioma)
04

Disease associations

Neurodegenerative disease (specifically Spinocerebellar ataxia type 8)Cancer (Breast cancer, Gliomas)
05

Safety considerations

Aberrant upregulation associated with cancer progression and poor prognosis in breast cancerPotential contribution to neurodegeneration in spinocerebellar ataxiaNo approved drugs directly targeting ATXN8OS; safety profile unknown for targeted therapies
06

Interacting drugs

Temozolomide (TMZ; in glioma chemoresistance studies)
07

Biomarkers

Overexpression can serve as a biomarker for breast cancer prognosis (poor outcome)May act as a biomarker for chemotherapy resistance in glioma

Beyond the preview

Go deeper on Ataxin 8 opposite strand long non-coding RNA (ATXN8OS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ataxin 8 opposite strand long non-coding RNA (ATXN8OS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call